CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Phase 1

Terminated

Conditions: Neoplasm Metastasis

Interventions: Drug: CC-90003

First Posted Date: 2014-12-09

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 19

Registration Number: NCT02313012

Locations: 🇺🇸
Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, California, United States
🇺🇸
Smilow Cancer Center, New Haven, Connecticut, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 2 locations

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Phase 1

Completed

Conditions: Pancreatic Neoplasms
Breast Neoplasms

Interventions: Drug: nab-Paclitaxel
Drug: Nivolumab
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2014-12-05

Last Posted Date: 2019-05-31

Lead Sponsor: Celgene

Target Recruit Count: 114

Registration Number: NCT02309177

Locations: 🇺🇸
Northwestern University-NMDTI, Chicago, Illinois, United States
🇺🇸
Dana-Farber / Harvard Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ohio State Medical Center, Columbus, Ohio, United States

and more 12 locations

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

Phase 2

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: nab-Paclitaxel
Drug: Gemcitabine
Drug: Chemoradiation
Drug: Capecitabine
Procedure: Surgery

First Posted Date: 2014-11-25

Last Posted Date: 2019-03-20

Lead Sponsor: Celgene

Target Recruit Count: 107

Registration Number: NCT02301143

Locations: 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸
Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸
Tufts - New England Medical Center, Boston, Massachusetts, United States

and more 39 locations

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1a
Drug: Ozanimod
Drug: Placebo to ozanimod
Drug: Placebo to interferon beta-1a

First Posted Date: 2014-11-19

Last Posted Date: 2020-11-25

Lead Sponsor: Celgene

Target Recruit Count: 1346

Registration Number: NCT02294058

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Neurological Research Institute Inc, Columbus, Ohio, United States
🇺🇸
The Polyclinic, Seattle, Washington, United States

and more 220 locations

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: nab-Paclitaxel
Drug: Carboplatin

First Posted Date: 2014-11-13

Last Posted Date: 2018-12-07

Lead Sponsor: Celgene

Target Recruit Count: 40

Registration Number: NCT02289456

Locations: 🇺🇸
University Cancer Institute, Boynton Beach, Florida, United States
🇺🇸
Ochsner Clinic Nephrology, New Orleans, Louisiana, United States
🇺🇸
University of RochesterJames P. Wilmont Cancer Center, Rochester, New York, United States

and more 5 locations

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Phase 3

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Placebo
Drug: lenalidomide
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: prednisone
Drug: vincristine

First Posted Date: 2014-11-06

Last Posted Date: 2023-06-22

Lead Sponsor: Celgene

Target Recruit Count: 570

Registration Number: NCT02285062

Locations: 🇺🇸
Local Institution - 151, Dallas, Texas, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸
Local Institution - 161, Philadelphia, Pennsylvania, United States

and more 155 locations

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Oral Azacitidine
Drug: Durvalumab

First Posted Date: 2014-11-02

Last Posted Date: 2024-10-04

Lead Sponsor: Celgene

Target Recruit Count: 65

Registration Number: NCT02281084

Locations: 🇧🇪
Local Institution - 800, Liège, Belgium
🇵🇱
Local Institution - 900, Warszawa, Poland
🇪🇸
Local Institution - 300, Granada, Spain

and more 86 locations

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Lenalidomide

First Posted Date: 2014-10-31

Last Posted Date: 2022-08-19

Lead Sponsor: Celgene

Target Recruit Count: 389

Registration Number: NCT02279654

Locations: 🇺🇸
Local Institution - 0002, Centre City, New Jersey, United States
🇺🇸
Local Institution - France, No City Provided, New Jersey, United States
🇺🇸
Local Institution - 0001, Centre City, New Jersey, United States

and more 143 locations

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Phase 1

Completed

Conditions: Chondrosarcoma
Solid Tumor
Glioma
Intrahepatic Cholangiocarcinoma
Angioimmunoblastic T-cell Lymphoma

Interventions: Drug: Enasidenib

First Posted Date: 2014-10-24

Last Posted Date: 2021-02-23

Lead Sponsor: Celgene

Target Recruit Count: 21

Registration Number: NCT02273739

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Neoplasms

Interventions: Drug: CC-486

First Posted Date: 2014-10-21

Last Posted Date: 2018-12-12

Lead Sponsor: Celgene

Target Recruit Count: 36

Registration Number: NCT02269943

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy